Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. ACN
7. IBM
8. NKE
9. MU
10. AWK

Go back to Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity

Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY)

August 8, 2025 7:10 AM EDT

Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $1,135.00 price target on Eli Lilly (NYSE: LLY)

The analyst comments "We believe we are at an inflection point for "The Broadening" of GLP-1 use, which will extend beyond US-based early adopters to... More